Clinical trial
Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study
NCT04950647 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study
- Lead sponsor
- Peking University Third Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 1, 2020
- Completion date
- December 31, 2022
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.